Acadia Pharmaceuticals (ACAD) Return on Capital Employed (2011 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Return on Capital Employed of 6.32% for Q1 2026, down 2106.0% year-over-year from 0.32% in Q1 2025, and down 29.38% quarter-over-quarter from 8.96% in Q4 2025.
Acadia Pharmaceuticals (ACAD) Return on Capital Employed (2011 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 6.32% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 2106.0% year-over-year to 6.32%; the TTM figure through Mar 2026 stood at 6.32% (down 2106.0% YoY), while the FY2025 annual figure was 9.54%, down 3071.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 6.32%, down from 8.96% in the prior quarter.
- The five-year high for Return on Capital Employed was 33.57% in Q4 2024, with the low at 47.62% in Q4 2022.
- The 5-year median for Return on Capital Employed is 0.97% (2024), against an average of 8.46%.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed surged 5473 bps in 2024, then slumped 2462 bps in 2025.
- Acadia Pharmaceuticals' Return on Capital Employed stood at 47.62% in 2022, then surged by 65 bps to 16.81% in 2023, then soared by 300 bps to 33.57% in 2024, then plunged by 73 bps to 8.96% in 2025, then slipped by 29 bps to 6.32% in 2026.
- Business Quant data shows ACAD's Return on Capital Employed at 6.32% in Q1 2026, 8.96% in Q4 2025, and 26.14% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn | 6.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.58% |
| Mar 31, 2026 | 6.32% |
| Dec 31, 2025 | 8.96% |
| Sep 30, 2025 | 26.14% |
| Jun 30, 2025 | 27.90% |
| Mar 31, 2025 | 27.39% |
| Dec 31, 2024 | 33.57% |
| Sep 30, 2024 | 18.66% |
| Jun 30, 2024 | 4.17% |
| Mar 31, 2024 | -0.97% |
| Dec 31, 2023 | -16.81% |
| Sep 30, 2023 | -36.07% |
| Jun 30, 2023 | -27.65% |
| Mar 31, 2023 | -41.32% |
| Dec 31, 2022 | -47.62% |
| Sep 30, 2022 | -45.25% |
| Jun 30, 2022 | -41.26% |
| Mar 31, 2022 | -39.94% |
| Dec 31, 2021 | -27.81% |
| Sep 30, 2021 | -30.49% |